Search results for "AGENTS"

showing 10 items of 7330 documents

Silicate modulates the cross-talk between osteoblasts (SaOS-2) and osteoclasts (RAW 264.7 cells): inhibition of osteoclast growth and differentiation

2012

It has been shown that inorganic monomeric and polymeric silica/silicate, in the presence of the biomineralization cocktail, increases the expression of osteoprotegerin (OPG) in osteogenic SaOS-2 sarcoma cells in vitro. In contrast, silicate does not affect the steady-state gene expression level of the osteoclastogenic ligand receptor activator of NF-κB ligand (RANKL). In turn it can be expected that the concentration ratio of the mediators OPG/RANKL increases in the presence of silicate. In addition, silicate enhances the growth potential of SaOS-2 cells in vitro, while it causes no effect on RAW 264.7 cells within a concentration range of 10-100 µM. Applying a co-cultivation assay system,…

musculoskeletal diseasesCell SurvivalCellular differentiationmedicine.medical_treatmentAcid PhosphataseMineralogyOsteoclastsCell Count02 engineering and technologyCell CommunicationBiochemistryCell Line03 medical and health sciencesMiceOsteoprotegerinOsteoclastOsteogenesismedicineAnimalsHumansMolecular BiologyRAW 264.7 Cells030304 developmental biologyTartrate-resistant acid phosphataseCell Proliferation0303 health sciencesOsteoblastsbiologyBone Density Conservation AgentsChemistryTartrate-Resistant Acid PhosphataseMacrophagesSilicatesRANK LigandCell DifferentiationCell Biology021001 nanoscience & nanotechnologyCoculture TechniquesCell biologyIsoenzymesmedicine.anatomical_structureCytokineCell cultureRANKLbiology.protein0210 nano-technologyJ. Cell. Biochem.
researchProduct

Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an…

2020

Introduction Pharmacokinetic interaction of high-dose methotrexate (MTX) and other concomitantly administered renally secreted medicinal products may lead to insufficient methotrexate serum level decrease and significant MTX toxicity. Case report We report the case of an 18-year-old male patient treated with high-dose MTX for an osteosarcoma and with high-dose piperacillin-tazobactam at the same time. MTX serum levels were severely elevated 24 hours after the MTX infusion and did not decrease in accordance with the specific calcium folinate rescue protocol. The patient experienced renal failure accompanied by neurological symptoms, most consistent with MTX-related renal and CNS toxicity. Ma…

musculoskeletal diseasesMaleAntimetabolites AntineoplasticAdolescentBone Neoplasms030204 cardiovascular system & hematologyPharmacology03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Drug InteractionsRenal InsufficiencyPiperacillinOsteosarcomabusiness.industryNeurotoxicitymedicine.diseaseHigh dose methotrexateAnti-Bacterial AgentsMethotrexateOncology030220 oncology & carcinogenesisPiperacillin/tazobactamOsteosarcomaMethotrexateNeurotoxicity SyndromesbusinessPharmacokinetic interactionmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct

Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery

2010

Background: According to some current guidelines, extended thromboprophylaxis after hip and knee arthroplasties is recommended. Outpatient prophylaxis with low molecular weight heparins (LMWH) is an important part of this prophylaxis, although the rates of adherence to these regimens is not known. Questions/purposes: We determined (1) the degree of nonadherence (NA) of patients with LMWH outpatient prophylaxis, and (2) whether specific independent factors explain NA. Methods: NA was determined by syringe count and by indirect and direct questions to patients. We defined six different NA indicators. To identify factors explaining LMWH NA, we used three different logistic regression models. R…

musculoskeletal diseasesMaleQuestionnairesmedicine.medical_specialtyHealth Knowledge Attitudes PracticeTime Factorsmedicine.drug_classmedicine.medical_treatmentArthroplasty Replacement HipLow molecular weight heparinRisk AssessmentInjectionsMedication AdherenceAmbulatory careFibrinolytic AgentsClinical ResearchRisk FactorsInternal medicineSurveys and QuestionnairesGermanyAmbulatory CareMedicineHumansOrthopedics and Sports Medicine/dk/atira/pure/core/keywords/559092180Arthroplasty Replacement KneeAgedbusiness.industryAnticoagulantHealth sciencesThrombosisGeneral MedicineHeparinHeparin Low-Molecular-Weightmedicine.diseaseThrombosisArthroplastySurgeryTelephoneLogistic ModelsTreatment OutcomeOrthopedic surgerySurgeryFemalebusinessFibrinolytic agentmedicine.drug
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

Spinal anaesthesia in a patient with post-spine surgery dural ectasia.

2013

Dural sac ectasia is a very infrequent anatomical abnormality, usually caused by connective tissue diseases, as Marfan syndrome. Very few cases have been described being a consequence of a previous spine surgical procedure. We describe the case of an elderly patient who should be operated on twice due to sub-occlusive colon disease. Surgery was performed under spinal anaesthesia. A dural sac ectasia was suspected after the first procedure and the abdominal X-ray was reviewed. The characteristics of the anatomical alteration and the course of both anaesthetic procedures were described. X-ray and CT images were provided.

musculoskeletal diseasesMarfan syndromeMalemedicine.medical_specialtymedicine.medical_treatmentDura materMegacolonPeritonitisCritical Care and Intensive Care MedicineAnesthesia SpinalFatal OutcomePostoperative ComplicationsEctasiaColostomySurgical Wound DehiscencemedicinePressureHumansColectomyInjections SpinalColectomyAbdomen AcuteAged 80 and overSigmoid DiseasesMegacolonbusiness.industryDural ectasiaColostomyLaminectomyLaminectomymedicine.diseaseBupivacaineCombined Modality TherapySurgeryAnti-Bacterial AgentsAnesthesiology and Pain Medicinemedicine.anatomical_structureDura MaterbusinessDilatation PathologicIntestinal VolvulusRevista espanola de anestesiologia y reanimacion
researchProduct

Sicilian pistachio (Pistacia vera L.) nut inhibits expression and release of inflammatory mediators and reverts the increase of paracellular permeabi…

2014

Background Dietary approaches to control inflammatory bowel diseases (IBD) may include proanthocyanidin-rich foods. Our previous research showed that a hydrophilic extract from Sicilian pistachio nut (HPE) contains sub- stantial amounts of proanthocyanidins and possesses anti- inflammatory activities. Purpose We studied the effects of HPE and of its poly- meric proanthocyanidin fraction (PPF) in a cell model that simulated some conditions of IBD, consisting of interleukin (IL)-1b-stimulated Caco-2 cells. Methods HPE was prepared by Pistacia vera L. nuts, and PPF was isolated from HPE by adsorbance chromatogra- phy. Proanthocyanidins were quantified as anthocyanidins after acidic hydrolysis.…

musculoskeletal diseasesPistachio nut Inflammation Intestinal epithelium Polyphenols Proanthocyanidinscongenital hereditary and neonatal diseases and abnormalitiesCellInterleukin-1betaAnti-Inflammatory AgentsMedicine (miscellaneous)BiologyPharmacologyPermeabilityCell membraneSettore BIO/10 - BiochimicamedicineHumansNutsProanthocyanidinsViability assayIntestinal MucosaCell ProliferationNutrition and DieteticsPistaciaInterleukin-6Interleukin-8NF-kappa BEpithelial Cellsbiology.organism_classificationIntestinal epitheliumIntestinesmedicine.anatomical_structureProanthocyanidinBiochemistryCaco-2Cyclooxygenase 2Paracellular transportPistaciaCaco-2 Cells
researchProduct

Successful treatment of primary chronic osteomyelitis in SAPHO syndrome with bisphosphonates.

2008

Summary The treatment of the painful osteomyelitis in patients with SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) is often a problem. A 53-year-old woman had experienced palmo-plantar pustular skin lesions for four years, and in the past two years complained about progressive breath-and movement-dependent pain of the sternum. On examination she had extensive palmoplantar pustules and a painful swelling in the area of the right sternoclavicular joint. The three-phase bone scintigraphy showed a strong focal enrichment in the right sternoclavicular joint and at the transition from the manubrium to the corpus sterni suggesting active osteo-chondritis. Initially prednisolo…

musculoskeletal diseasesSAPHO syndromemedicine.medical_specialtyHyperostosisDermatologySynovitismedicineHumansAcnemedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteomyelitisAcquired Hyperostosis SyndromeOsteomyelitisMiddle Agedmedicine.diseasePustulosisDermatologySurgeryTreatment OutcomeBone scintigraphyChronic DiseaseFemaleOsteitismedicine.symptombusinessJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

Chromogenic detection of nerve agent mimics

2008

The current rise in international concern over criminal terrorist attacks via chemical warfare (CW) agents has resulted in an increasing interest in the detection of these lethal chemicals. Among CW species, nerve agents are extremely dangerous and their high toxicity and ease of production underscore the need to detect these deadly chemicals via quick and reliable procedures. A number of detection systems have been developed, most of them based on enzymatic and physical methodologies. However, these usually show limitations such as low selectivity, lack of portability and a certain complexity in their use. An alternative to these classical methods that has been gaining interest in recent y…

musculoskeletal diseasesTertiary amineUNESCO::QUÍMICANerve agent mimicsElectron donorBiosensing TechniquesUNESCO::ASTRONOMÍA Y ASTROFÍSICA:QUÍMICA [UNESCO]Reductive aminationCatalysischemistry.chemical_compoundOrganophosphorus CompoundsMaterials ChemistryMoietyChemical Warfare Agentsskin and connective tissue diseasesChromogenic protocol ; Nerve agent mimics ; Internationalchemistry.chemical_classificationChromogenic protocolMolecular StructureChromogenicChemistryfungiMetals and AlloysGeneral ChemistryElectron acceptorCombinatorial chemistrySurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsDiethyl chlorophosphatebody regionsKineticsstomatognathic diseasesChromogenic CompoundsInternationalCeramics and CompositesColorimetryHypsochromic shiftAzo Compounds:ASTRONOMÍA Y ASTROFÍSICA [UNESCO]
researchProduct

Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data fr…

2011

Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) consumption is strictly related to a high gastrointestinal and cardiovascular mortality and morbidity rate. Osteoarthritis Research Society International (OARSI) recommendations in patients with symptomatic hip or knee OA stated that NSAIDs should be used at the lowest effective dose but their long-term use should be avoided if possible. OARSI guidelines for the treatment of the hip OA include the use of viscosupplementation, which aims to restore physiological and rheological features of the synovial fluid. Objective: Aim of this multicentric, open and retrospective study is to investigate if NSAID consumption may be reduced by t…

musculoskeletal diseaseshipultrasoundintra-articular injection; nsaid; hyaluronic acid; hip; ultrasound; osteoarthritisAnti-Inflammatory Agents Non-SteroidalMiddle AgedHip viscosupplementation ultra-sound guidanceOsteoarthritis HipInjections Intra-ArticularosteoarthritisSettore MED/33 - Malattie Apparato LocomotoreHumansUltrasonicsRegistriesHyaluronic Acidnsaidintra-articular injectionAgedFollow-Up StudiesPain MeasurementRetrospective StudiesUltrasonography
researchProduct